Literature DB >> 21810971

Indolent mantle cell lymphoma.

Michelle Furtado, Simon Rule.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21810971      PMCID： PMC3148899          DOI： 10.3324/haematol.2011.047357

Source DB:  PubMed          Journal:  Haematologica        ISSN： 0390-6078            Impact factor:   9.941


× No keyword cloud information.
  20 in total

Review 1.  bcl-1, t(11;14), and mantle cell-derived lymphomas.

Authors:  M Raffeld; E S Jaffe
Journal:  Blood       Date:  1991-07-15       Impact factor: 22.113

2.  Sox4-deficiency syndrome in mice is an animal model for common trunk.

Authors:  J Ya; M W Schilham; P A de Boer; A F Moorman; H Clevers; W H Lamers
Journal:  Circ Res       Date:  1998-11-16       Impact factor: 17.367

3.  The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma.

Authors:  Andreas Rosenwald; George Wright; Adrian Wiestner; Wing C Chan; Joseph M Connors; Elias Campo; Randy D Gascoyne; Thomas M Grogan; H Konrad Muller-Hermelink; Erlend B Smeland; Michael Chiorazzi; Jena M Giltnane; Elaine M Hurt; Hong Zhao; Lauren Averett; Sarah Henrickson; Liming Yang; John Powell; Wyndham H Wilson; Elaine S Jaffe; Richard Simon; Richard D Klausner; Emilio Montserrat; Francesc Bosch; Timothy C Greiner; Dennis D Weisenburger; Warren G Sanger; Bhavana J Dave; James C Lynch; Julie Vose; James O Armitage; Richard I Fisher; Thomas P Miller; Michael LeBlanc; German Ott; Stein Kvaloy; Harald Holte; Jan Delabie; Louis M Staudt
Journal:  Cancer Cell       Date:  2003-02       Impact factor: 31.743

4.  Immunoglobulin VH somatic hypermutation in mantle cell lymphoma: mutated genotype correlates with better clinical outcome.

Authors:  Raymond Lai; Shilo V Lefresne; Bevin Franko; David Hui; Imran Mirza; Adnan Mansoor; Hesham M Amin; Yupo Ma
Journal:  Mod Pathol       Date:  2006-09-15       Impact factor: 7.842

5.  A subset of t(11;14) lymphoma with mantle cell features displays mutated IgVH genes and includes patients with good prognosis, nonnodal disease.

Authors:  Jenny Orchard; Richard Garand; Zadie Davis; Gavin Babbage; Surinder Sahota; Estella Matutes; Daniel Catovsky; Peter W Thomas; Hervé Avet-Loiseau; David Oscier
Journal:  Blood       Date:  2003-02-27       Impact factor: 22.113

6.  Leukemic involvement is a common feature in mantle cell lymphoma.

Authors:  Ana Ferrer; Itziar Salaverria; Francesc Bosch; Neus Villamor; María Rozman; Silvia Beà; Eva Giné; Armando López-Guillermo; Elías Campo; Emili Montserrat
Journal:  Cancer       Date:  2007-06-15       Impact factor: 6.860

7.  Gene targeting reveals a widespread role for the high-mobility-group transcription factor Sox11 in tissue remodeling.

Authors:  Elisabeth Sock; Stefanie D Rettig; Janna Enderich; Michael R Bösl; Ernst R Tamm; Michael Wegner
Journal:  Mol Cell Biol       Date:  2004-08       Impact factor: 4.272

8.  A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma.

Authors:  Eva Hoster; Martin Dreyling; Wolfram Klapper; Christian Gisselbrecht; Achiel van Hoof; Hanneke C Kluin-Nelemans; Michael Pfreundschuh; Marcel Reiser; Bernd Metzner; Hermann Einsele; Norma Peter; Wolfram Jung; Bernhard Wörmann; Wolf-Dieter Ludwig; Ulrich Dührsen; Hartmut Eimermacher; Hannes Wandt; Joerg Hasford; Wolfgang Hiddemann; Michael Unterhalt
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113

9.  The subcellular Sox11 distribution pattern identifies subsets of mantle cell lymphoma: correlation to overall survival.

Authors:  Xiao Wang; A Charlotta Asplund; Anna Porwit; Jenny Flygare; C I Edvard Smith; Birger Christensson; Birgitta Sander
Journal:  Br J Haematol       Date:  2008-08-20       Impact factor: 6.998

10.  Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma.

Authors:  Sara Ek; Michael Dictor; Mats Jerkeman; Karin Jirström; Carl A K Borrebaeck
Journal:  Blood       Date:  2007-10-12       Impact factor: 22.113
View more
  13 in total

1.  Consolidative therapy with stem cell transplantation improves survival of patients with mantle cell lymphoma after any induction regimen.

Authors:  Nishitha Reddy; John P Greer; Stacey Goodman; Adetola Kassim; David S Morgan; Wichai Chinratanalab; Stephen Brandt; Brian Englehardt; Olalekan Oluwole; Madan H Jagasia; Bipin N Savani
Journal:  Exp Hematol       Date:  2012-01-21       Impact factor: 3.084

2.  Leukemic non-nodal mantle cell lymphomas have a distinct phenotype and are associated with deletion of PARP1 and 13q14.

Authors:  Mathieu Gallo; Valère Cacheux; Laure Vincent; Caroline Bret; Ariane Tempier; Caroline Guittard; Alexandra Macé; Nicolas Leventoux; Valérie Costes; Vanessa Szablewski
Journal:  Virchows Arch       Date:  2016-09-07       Impact factor: 4.064

3.  Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma.

Authors:  Oscar Calzada; Jeffrey M Switchenko; Joseph J Maly; Kristie A Blum; Natalie Grover; Stephanie Mathews; Steven I Park; Max Gordon; Alexey Danilov; Narendranath Epperla; Timothy S Fenske; Mehdi Hamadani; Christopher R Flowers; Jonathon B Cohen
Journal:  Leuk Lymphoma       Date:  2018-06-18

4.  CD5-negative mantle cell lymphoma: clinicopathologic features of an indolent variant that confers a survival advantage.

Authors:  Arshia Soleimani; Alba Navarro; Delong Liu; Sarah E M Herman; Shih-Sung Chuang; Irma Slavutsky; Marina Narbaitz; Hana Safah; John Schmieg; John Lefante; Mark Roschewski; Wyndham H Wilson; Adrian Wiestner; Nakhle S Saba
Journal:  Leuk Lymphoma       Date:  2021-11-15

Review 5.  Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature.

Authors:  Reza Setoodeh; Stuart Schwartz; Peter Papenhausen; Ling Zhang; Elizabeth M Sagatys; Lynn C Moscinski; Haipeng Shao
Journal:  Int J Clin Exp Pathol       Date:  2013-01-15

6.  CD200 expression in mantle cell lymphoma identifies a unique subgroup of patients with frequent IGHV mutations, absence of SOX11 expression, and an indolent clinical course.

Authors:  Zhihong Hu; Yi Sun; Ellen J Schlette; Guilin Tang; Shaoying Li; Jie Xu; C Cameron Yin; Ken H Young; Keyur Pravinchandra Patel; Roberto N Miranda; Maitrayee Goswami; Michael Wang; Jeffrey L Jorgensen; L Jeffrey Medeiros; Sa A Wang
Journal:  Mod Pathol       Date:  2017-10-06       Impact factor: 7.842

Review 7.  Smoldering mantle cell lymphoma.

Authors:  Haige Ye; Aakash Desai; Dongfeng Zeng; Krystle Nomie; Jorge Romaguera; Makhdum Ahmed; Michael L Wang
Journal:  J Exp Clin Cancer Res       Date:  2017-12-15

Review 8.  Progress in molecular feature of smoldering mantle cell lymphoma.

Authors:  Panruo Jiang; Aakash Desai; Haige Ye
Journal:  Exp Hematol Oncol       Date:  2021-07-13

Review 9.  SNPs Array Karyotyping in Non-Hodgkin Lymphoma.

Authors:  Maryam Etebari; Mohsen Navari; Pier Paolo Piccaluga
Journal:  Microarrays (Basel)       Date:  2015-11-12

Review 10.  SOX11 is a biomarker for cyclin D1-negative mantle cell lymphoma.

Authors:  Roshni Narurkar; Mohammad Alkayem; Delong Liu
Journal:  Biomark Res       Date:  2016-03-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.